USFDA approvals can unlock $1 bn biosimilar business for Biocon in the US

We have at least a five-year head start in biosimilars compared with other Indian drugmakers, says Mazumdar-Shaw

Biocon Ltd, the only Indian drugmaker to win approval to sell copies of a biologic drug in the US, expects its business in that nascent sector will generate $1 billion in revenue by 2025 as it clears further regulatory hurdles this year.
 
The company’s other leading drug candidates are back on track for approval after hiccups in the U.S. and Europe, said Managing Director Kiran Mazumdar-Shaw in an interview. Biocon is also exploring the sale of part of its stake in its publicly traded contract research arm, Syngene International Ltd., to fund its growing ambitions in the biologics business,